Isis Pharmaceutical (ISIS -3.6%) shares slip lower despite the FDA's announcement that it's...

|By:, SA News Editor

Isis Pharmaceutical (ISIS -3.6%) shares slip lower despite the FDA's announcement that it's recommended approval of Kynamro for the treatment of Hypercholesterolemia, as analysts dig deeper into the recommendation's details, which the FDA is not required to follow. Jefferies notes that the approval could be "very limited," while a Seeking Alpha report suggests that competitor Aegerion Pharma's (AEGR -5%) Lomitapide could be a better choice, with a more decisive vote from the committee and none of the safety concerns of Kynamro.